EW Stock Recent News

Health Care and Energy sectors outperform in 2025, with the Health Care Select Sector SPDR Fund ETF up 7% YTD, while Edwards Lifesciences lags. Despite a solid Q4 earnings beat, EW's shares remain undervalued with a reduced P/E multiple of 33x, yielding a price target of $84. Key risks include slower TAVR growth in Japan and hospital demand uncertainties, but long-term sales growth targets remain optimistic.

SUNNYVALE, Calif.--(BUSINESS WIRE)--Intuitive Ventures today announced the appointment of Terri Burke, former head medtech investments at Epidarex Capital and a seasoned operator, as Senior Partner and Dr. Ross Jaffe, a co-founder of Versant Ventures, as Venture Advisor. Both medtech veterans, they will help support the continued growth of Intuitive Ventures in investing in start-ups reimagining the future of minimally invasive care. With more than two decades of medtech investing and operation.

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the TD Cowen 45th Annual Health Care Conference on Tuesday, Mar. 4, 2025. Scott Ullem, chief financial officer, is scheduled to present at 9:50 a.m. ET. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived version accessible later the same day. About Edwards Lifesciences Edwards Life.

EW stock is on investors' radars due to the promising structural heart opportunities following the divestment of the Critical Care arm.

On Tuesday, Edwards Lifesciences EW reported fourth-quarter sales of $1.39 billion, beating the consensus of $1.36 billion. This represents a 9% year-over-year growth, supported by gains in all product groups.

Edwards Lifesciences reports strong contributions from all product groups ??? TAVR, TTMT and surgical structural heart?

Edwards Lifesciences Corporation (NYSE:EW ) Q4 2024 Earnings Conference Call February 11, 2025 5:00 PM ET Company Participants Mark Wilterding - Senior Vice President, Investor Relations Bernard Zovighian - Chief Executive Officer Scott Ullem - Corporate Vice President and Chief Financial Officer Daveen Chopra - Corporate Vice President, TMTT Larry Wood - Corporate Vice President and Group President of TAVR and SSH Conference Call Participants David Roman - Goldman Sachs Robbie Marcus - JPMorgan Larry Biegelsen - Wells Fargo Pito Chickering - Deutsche Bank Travis Steed - Bank of America Vijay Kumar - Evercore ISI Frederick Wise - Stifel Matthew Miksic - Barclays Matthew Taylor - Jefferies Joanne Wuensch - Citibank Mark Wilterding [Starts Abruptly] included in the press release and accompanying financial schedules and then use the remaining time for Q&A. Please note that management will be making forward-looking statements that are based on estimates, assumptions and projections.

Although the revenue and EPS for Edwards Lifesciences (EW) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Edwards Lifesciences beat analysts' estimate for fourth-quarter profit on Tuesday, helped by strong demand for its artificial heart valves and other medical devices.

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter and full-year ended Dec. 31, 2024. Highlights and Outlook Q4 sales grew 9% to $1.39 billion1, better than expected, with strength across all product groups Q4 TAVR sales grew 6%; constant currency2 sales grew 5% Q4 TMTT sales grew 88% to $105 million with increasing contribution to Edwards' growth Q4 EPS of $0.581; adjusted2 EPS of $0.59, driven by strong top-line performance Presen.